Expanding the Target Range of a Type IIB Cas9 Enzyme Through Evolution-Guided Engineering
Loading...
Date
Authors
Type
Examensarbete för masterexamen
Master's Thesis
Master's Thesis
Programme
Model builders
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The discovery and development of CRISPR-Cas9 has revolutionized genome edit
ing and enabled the development of novel therapeutic approaches. However, many
disease-causing mutations are still inaccessible due to the absence of relevant PAM
sequences within the therapeutic editing window. This master’s thesis employed di
rected evolution to generate ePsCas9 variants with expanded PAM recognition capa
bilities, enabling the targeting of disease-causing mutations previously inaccessible.
Different library generation approaches and selection strategies were systematically
explored. Selected variants obtained from the directed evolution were screened using
a luciferase reporter system and four lead candidates (pCN1, pCN12, pCN15, and
pCN27) were identified. A novel PAM-determination assay was established to profile
motif recognition, revealing that pCN1, pCN12, and pCN15 exhibit relaxed recog
nition of NRG or NDG motifs. This PAM assay provides a valuable tool for char
acterizing Cas9 variants and was successfully applied to determine the NNNGAA
recognition motif of another novel proprietary AstraZeneca Cas9 enzyme. Genome
editing analysis demonstrated that pCN12 and pCN15 achieved equal or greater
activity than the established SpRY variant at two of three NAG-PAM target se
quences, while pCN27 showed enhanced NGC-PAM activity compared to wild-type
ePsCas9.
Description
Keywords
CRISPR-Cas9, directed evolution, ePsCas9, library generation, selection system
